Cancer

Get Email Updates

Resource Centers

Cancer Bloggers

Cancer Guide

Maryann Gromisch RN Guide

Have a question? We're here to help. Ask the Community.

ASK

Free Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER!

Cardiotoxicity of Chemotherapy Agents for Cancer

By Linda Fugate PhD HERWriter November 28, 2011 - 7:03am
 
Rate This
0 comments View Comments

No one wants to be cured of cancer just to die of a heart attack. Unfortunately, many of the chemotherapy agents used to treat cancer have damaging effects on the heart. Physicians must carefully balance the risks and benefits of these powerful drugs.

Dr. Manabu Minami of Kyoto University Hospital, Japan, provided a review of cardiovascular side effects of cancer drugs. “Over the past few decades, cancer treatment has dramatically evolved,” Minami wrote.

Advances in the number and effectiveness of chemotherapy agents offer better results in treating cancer. However, some of the newer molecular target drugs are comparable to the well-known anthracyclines in terms of cardiotoxicity.

Heart disease can develop at any time after chemotherapy, even decades later. Children treated for cancer have a 15.1-fold increased risk of congestive heart disease, a 10.4-fold greater risk of coronary artery disease, and a 9.3-fold greater risk of cerebrovascular events, such as stroke, compared to their siblings who did not have childhood cancer. The risk of cardiovascular disease for these long-term survivors is greater than their risk for a second cancer.

The overall risk of cancer increases with age, so most patients who receive chemotherapy are also at risk for cardiovascular disease. Women have higher rates than men of cardiac toxicity from the well-known anthracyclines. Other risk factors include high blood pressure, heart conditions prior to cancer therapy, radiation therapy to the chest, use of multiple cancer drugs, and cumulative dose.

Minami described the following cytotoxic drugs to have significant cardiac toxicity:

1.Anthracyclines
2.Taxanes (paclitaxel and docetaxel)
3.Flurorpyrimidine (5-FU)
4.Cyclophosphamide
5.Cisplatin

For molecular target drugs, also called targeted chemotherapy, Minami reported cardiac toxicity issues for the following:

1.Trastuzumab
2.Cetuximab
3.Lapatinib
4.Bevacizumab
5.Sunitinib
6.Sorafenib
7.Imatinib
8.Rituximab

Dr. Aarif Y. Khakoo of The University of Texas M. D.

 
Rate This
0 comments View Comments

We value and respect the experiences of all of our HERWriters, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice although we hope you can gain knowledge from their insight.

Tags

Add a CommentComments

There are no comments yet. Be the first one and get the conversation started!

Image CAPTCHA
By hitting submit, you agree to EmpowHER's terms of service and privacy policy

Improved

616 Health

Changed

293 Lives

Saved

210 Lives
3 lives impacted in the last 24 hrs Learn More

Health Theater Videos

View More Videos

Take our Featured Poll

Have you ever participated in a clinical trial?:
View Results